and Spectrum Pharmaceuticals Inc., of Irvine, Calif., reported the final progression-free survival results from the Phase III SPARC registration trial of satraplatin, a platinum-based agent

Secondary endpoints will evaluate the duration of response, progression-free survival, overall survival, time to response and various safety and pharmacokinetic parameters

Forty-five patients may receive up to six 21-day cycles at various sites in the U.S. In addition to safety, the trial is investigating the efficacy of glufosfamide as determined by response rate, duration of response and progression-free survival based on changes in the serum tumor marker level CA-125, tumor assessments and overall survival

Endpoints include progression-free survival and overall survival

Onyx Pharmaceuticals Inc., of Emeryville, Calif., and Bayer Pharmaceuticals Corp., of West Haven, Conn., said results of a pivotal Phase III trial demonstrate that Nexavar (sorafenib) tablets doubled median progression-free survival in patients with advanced renal-cell carcinoma...Clinic Roundup

Secondary endpoints include duration of response, progression-free survival and overall survival

Secondary objectives include assessing progression-free survival, overall survival, and duration of response and to continue characterizing the pharmacokinetic and pharmacodynamic profiles of XL880

Point Therapeutics Inc., of Boston, said finalized data from its 55-patient Phase II study of talabostat in combination with docetaxel in Stage IIIb/IV non-small-cell lung cancer showed an overall median progression-free survival of four months and an overall median survival of 7.8 months

Genentech Inc., of South San Francisco, said results from the second interim analysis from the BCIRG 006 Phase III breast cancer study confirmed that, at a three-year median follow-up, Herceptin combined with Taxotere-based regimens significantly improved disease-free survival for women with early HER2-positive breast cancer

Genentech Inc., of South San Francisco, said an interim analysis showed that a randomized Phase III study of Avastin (bevacizumab) in combination with interferon alfa-2a therapy in patients with first-line metastatic renal-cell carcinoma met the primary analysis endpoint by significantly improving progression-free survival compared to interferon alfa-2a therapy alone

The 31-patient trial will measure the primary endpoints of reduction in PSA levels, reduction in tumor size and disease-free survival...The one-year progression-free survival and overall survival rates were 93 percent and 100 percent, respectively, and the two-year PFS and OS rates were 86 percent and 86 percent, respectively

Secondary endpoints will include overall survival time, response duration, percentage complete and partial responses, progression-free survival and treatment-related adverse events

Secondary endpoints include duration of remission, disease-free survival, overall survival, safety and 30-day mortality rate

involving 81 patients with Stage IV metastatic melanoma, the median progression-free survival - the time from randomization until death or objective tumor progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - improved from 1.84 months for those receiving paclitaxel alone to 3.68 months for patients who received STA-4783 plus paclitaxel

Secondary endpoints include progression-free survival, tumor response rates and quality-of-life scores

The median progression-free survival was 16 weeks, with a 26-week progression-free survival of 27 percent and median survival of 59 weeks

Sixty-one patients in the 212-patient trial who had clinical-benefit response with AP23573 - defined as tumor regression or disease stabilization - had a progression-free survival rate at six months of 70 percent, which nearly tripled that of the overall trial population of 24 percent...Median progression-free survival in that same patient subset was 36 weeks vs. 15 weeks in the overall trial population

The primary objective will be to assess safety, pharmacokinetics, tumor response rate and progression-free survival in patients receiving orally administered Panzem

The primary endpoint will be survival at six months, while tumor response rate and progression-free survival will be evaluated as secondary endpoints